MED (Medifast) Research & Development: $0.0 Mil (TTM As of Mar. 2026)


MED Medifast Inc MED
69 GF Score
Price $10.36
GF Value $8.75
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medifast Research & Development?

Medifast MED -2.45% 69 Research & Development is $0.0 Mil as of Mar. 2026. GuruFocus rates MED with a GF Score™ of 69/100 and a GF Value™ of $8.75 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medifast's Research & Development for the three months ended in Mar. 2026 was $0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

Medifast  (NYSE:MED) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medifast Research & Development Related Terms

Medifast Research & Development Historical Data

* Premium members only.

The historical data trend for Medifast's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medifast Research & Development Chart

Medifast Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medifast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MED
69GF Score
Medifast Inc MED
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medifast Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.0 Mil mean?
Medifast (MED) has a Research & Development of $0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medifast and its competitors.
Is Medifast's Research & Development too high?
Medifast's current Research & Development is $0.0 Mil. Overall, Medifast has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medifast's Research & Development compare to RGS and VGES?
Medifast's Research & Development of $0.0 Mil can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Personal Services company?
A good Research & Development depends on the Personal Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medifast and its competitors. Medifast's current Research & Development is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medifast stock overvalued right now?
Based on GuruFocus' analysis, Medifast (MED) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.75, compared to a current price of $10.36 — trading 18.4% above its estimated fair value. The current Research & Development is $0.0 Mil. Medifast's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medifast (MED), the current Research & Development is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medifast (MED) Overvalued in 2026?

Based on GuruFocus' analysis, Medifast stock appears to be overvalued. The current stock price of $10.36 is trading 18.4% above its estimated GF Value™ of $8.75. GuruFocus considers Medifast to be Modestly Overvalued.

Key valuation signals for MED:

  • Research & Development: $0.0 Mil
  • GF Value™: $8.75 vs. price of $10.36 (18.4% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medifast Business Description

Other Exchanges 0K05:UKMDF:Germany
Address 100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
69GF Score

Get the complete analysis for MED

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.36
Price
$8.75
GF Value